Quiescence: Quantitative differences, qualitative outcomes
Quiescence (from the Latin meaning ‘to become quiet’) is a state during which cells stop progressing through the cell cycle and cease to divide. However, quiescent cells retain the ability to start moving through the cell cycle again. Programmed quiescence of many types of cells, including stem cells, is essential for organisms to develop normally. Quiescence is also crucial for maintaining tissues in a healthy condition in adults. Unveiling the molecular machinery that regulates quiescence is, therefore, of paramount importance for understanding development and disease.
Insight into how quiescence is regulated has been obtained through studies on neuroblasts—a type of brain stem cell—in the fruit fly Drosophila. The neuroblasts become quiescent during the late stages of embryonic development and resume growing and dividing as the larva hatches. Studies carried out over the last few years have revealed that these cells exit the quiescent state in response to a nutritional stimulus (Chell and Brand, 2010; Sousa-Nunes et al., 2011).
Now, in eLife, Sen-Lin Lai and Chris Doe at the University of Oregon report that the amount of a protein called Prospero controls when neuroblasts enter quiescence (Lai and Doe, 2014). Unlike cells that divide symmetrically to produce two identical cells, neuroblasts divide asymmetrically to make a new neuroblast and a ganglion mother cell. The mature cells that make up the central nervous system develop from these ganglion mother cells. Prospero is one of several molecules that, by being unequally divided between the new neuroblast and the ganglion mother cell, give each cell its identity.
In the developing Drosophila central nervous system, Prospero is well known for its essential roles in repressing neuroblast self-renewal, stopping neuroblasts proliferating, and promoting the differentiation of the neuroblast into a final specialized cell type (Choksi et al., 2006). There is also evidence showing that Prospero can temporarily pause the cell cycle of a certain type of cell that generates the glial cells that support the neurons in the brain (Griffiths and Hidalgo, 2004).
The new results obtained by Lai and Doe demonstrate that, at the end of their proliferative phase, embryonic neuroblasts produce a brief, low-level pulse of Prospero that causes them to become quiescent. In addition, Lai and Doe found that introducing similar pulses of Prospero into cells experimentally can drive proliferating embryonic neuroblasts into premature quiescence (Figure 1).
The conclusion that Prospero is necessary for neuroblast quiescence is supported by evidence that appeared to show that a large number of neuroblasts fail to quiesce in mutant Drosophila embryos that are unable to produce Prospero. However, a lack of Prospero also results in the formation of neuroblast-like ganglion mother cells, which do not quiesce (Choksi et al., 2006; Lee et al., 2006). Therefore, Lai and Doe needed to implement a method that could tell apart neuroblast-like cells from bona fide neuroblasts.
To this end, taking advantage of the wealth of knowledge and tools developed over the years in Drosophila research, Lai and Doe made use of reporter genes that indicate when Notch signalling occurs. Notch is a protein that helps neighbouring cells to signal to each other. Unlike neuroblasts, cells derived from ganglion mother cells express a protein that inhibits Notch signalling. Therefore, if a neuroblast-like cell displays Notch signalling activity, it must be a neuroblast. This meant Lai and Doe were able to confirm that the cells they investigated were neuroblasts, and that a lack of Prospero does prevent quiescence.
The conclusion that Prospero is sufficient for quiescence is supported by experiments that introduced a low-level pulse of Prospero to cells, which resulted in many neuroblasts becoming quiescent. Here again, the multitasking nature of Prospero made experiments technically difficult, as high levels of Prospero can cause neuroblasts to differentiate and become a specialized cell (Choksi et al., 2006).
To rule out this possibility, Lai and Doe delivered a short pulse of Prospero using the TARGET method (McGuire et al., 2003), which controls when and where genes are expressed. Importantly, once Prospero levels returned to normal background levels, the resulting quiescent neuroblasts started proliferating again, confirming that neuroblasts exposed to a short pulse of Prospero do indeed become quiescent.
Lai and Doe have therefore established that different levels of Prospero control different behaviours in neuroblasts. When the level of Prospero is minimal, neuroblasts can divide asymmetrically to form a ganglion mother cell; a low-level pulse of Prospero drives proliferating neuroblasts into quiescence; and high levels force the neuroblasts to differentiate into a specialized cell type (Figure 1).
In mice, Prox1—the vertebrate form of Prospero—has several roles during retinal development: for example, it enables the embryonic cells that produce the different cells in the retina to exit the cell cycle; it is required for the specification of the cells that are responsible for allowing eyes to adjust to changing light conditions; and it is essential for maturing the cells that transmit signals from the photoreceptors. The analysis of individuals who had one non-functional copy of the Prox1 gene suggests that some of these functions may depend on how much Prox1 is present (Dyer, 2003). Prox1 has been linked to a variety of cancer types in humans in the last few years (Elsir et al., 2012).
Although so far limited to Drosophila embryonic neuroblasts, the results reported by Lai and Doe add a new case to the list of qualitatively different outcomes driven by quantitative differences. This is abundantly exploited in different contexts during development and, perhaps, might also be relevant for disease.
References
-
Transcription factor PROX1: its role in development and cancerCancer Metastasis Reviews 31:793–805.https://doi.org/10.1007/s10555-012-9390-8
Article and author information
Author details
Publication history
Copyright
© 2014, Pollarolo and Gonzalez
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,142
- views
-
- 59
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Stem Cells and Regenerative Medicine
Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, that is, regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells, and smooth muscle cells. Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.
-
- Stem Cells and Regenerative Medicine
Bone regeneration is mediated by skeletal stem/progenitor cells (SSPCs) that are mainly recruited from the periosteum after bone injury. The composition of the periosteum and the steps of SSPC activation and differentiation remain poorly understood. Here, we generated a single-nucleus atlas of the periosteum at steady state and of the fracture site during the early stages of bone repair (https://fracture-repair-atlas.cells.ucsc.edu). We identified periosteal SSPCs expressing stemness markers (Pi16 and Ly6a/SCA1) and responding to fracture by adopting an injury-induced fibrogenic cell (IIFC) fate, prior to undergoing osteogenesis or chondrogenesis. We identified distinct gene cores associated with IIFCs and their engagement into osteogenesis and chondrogenesis involving Notch, Wnt, and the circadian clock signaling, respectively. Finally, we show that IIFCs are the main source of paracrine signals in the fracture environment, suggesting a crucial paracrine role of this transient IIFC population during fracture healing. Overall, our study provides a complete temporal topography of the early stages of fracture healing and the dynamic response of periosteal SSPCs to injury, redefining our knowledge of bone regeneration.